Women Are More Infected and Seek Care Faster but Are Less Severely Ill: Gender Gaps in COVID-19 Morbidity and Mortality during Two Years of a Pandemic in Israel

Arielle Kaim 1,2,*, Shani Ben Shetrit 3 and Mor Saban 4,5

1 Department of Emergency and Disaster Management, Faculty of Medicine, School of Public Health, Sackler Tel Aviv University, Tel Aviv 6139001, Israel
2 Israel National Center for Trauma & Emergency Medicine Research, The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Center, Ramat Gan 5266202, Israel
3 The Buchmann Faculty of Law, Tel Aviv University, Tel Aviv 6139001, Israel
4 Health Technology Assessment and Policy Unit, The Gertner Institute for Epidemiology & Health Policy Research, Sheba Medical Center, Ramat Gan 5266202, Israel
5 Nursing Department, Sackler Faculty of Medicine, School of Health Professions, Tel-Aviv University, Tel Aviv 6139001, Israel

* Correspondence: akaim@tauex.tau.ac.il

Abstract: In the context of COVID-19 outcomes, global data have deduced a gender bias towards severe disease among males. The aim is to compare morbidity and mortality during two years of the COVID-19 pandemic in female and male patients with COVID-19, as well as to assess length of stay, time of health-seeking behavior after positive diagnosis, and vaccination differences. A retrospective-archive study was conducted in Israel from 1 March 2020 to 1 March 2022 (two consecutive years). Data were obtained from the Israeli Ministry of Health’s (MOH) open COVID-19 database. The findings indicate female infections are 1.12 times more likely, across almost all age groups, apart from the youngest (0–19) age groups. Despite this, the relative risk of severe illness, intubation and mortality is higher among men. In addition, our findings indicate that the mean number of days taken by unvaccinated men from positive diagnosis to hospital admission was greater than among unvaccinated women among the deceased population. The findings of this study reveal lessons learned from the COVID-19 global pandemic. Specifically, the study shows how human biological sex may have played a role in COVID-19 transmission, illness, and death in Israel. The conclusions of this study indicate that targeted approaches, which take into consideration sex and gender and the intersecting factors are necessary to engage in the fight against COVID-19 and ensure the most effective and equitable pandemic response.

Keywords: COVID-19; pandemic; gender; prevention; disparities

1. Introduction

Over two years into the COVID-19 pandemic, the virus continues to be an ongoing global threat, with over 635 million diagnosed cases and 6.6 million deaths worldwide as of 15 November 2022 [1]. At the initial stages of the pandemic, emphasis was initially placed on elderly or among those with preexisting health conditions as being at high-risk of contracting the virus or death; however, human biological sex has been documented to play a central role in heterogeneous infectious disease pathogenesis [2–4].

These clinical findings are consistent with previous outbreaks of highly pathogenic coronaviruses such as severe acute respiratory syndrome coronavirus (SARS-CoV-1) and the Middle East respiratory syndrome coronavirus (MERS-CoV), where men were more likely to have been infected and have worse outcomes [5,6].

In the context of COVID-19 outcomes, similarly, global data have deduced a gender bias towards severe disease among males [7–12]. Early reporting at the initial stages
of the pandemic from China, presented by several research teams, including Guan et al. (2020) [13], Zhao et al. (2020) [14], and Mo et al. (2020) [15], had already indicated that the majority of infected patients were male, with a predisposition toward more severe cases. Despite this, global data show that the incidence of COVID-19 among males and females is both country and regionally diversified [16]. For example, findings presented by Kocher et al. (2021) from six countries, including Belgium, Canada, Denmark, Portugal, South Korea, and Switzerland, reported more cases in women by at least six percentage points [17]. Even on the small spatial scale, spatio-analyses have documented variability in the determinants of COVID-19 spread [18]. Time is an additional significant component, where dynamism and variability have been observed regarding COVID-19 gender trends throughout different periods [19]. For example, Danielsen et al. (2022) indicated that 72.7% of the difference in mortality rate between men and women was accrued in the first seven weeks of the pandemic, whereas, later, these differences were attenuated in subsequent phases.

Proponents of the above conclusions have explored why men are more vulnerable to worse outcomes, where both biological (sex), such as weaker immune responses, and socio-cultural behavioral (gender) factors have found to be at play [20]. Bwire (2020) suggests several possible factors that explain the gender gap, including the higher expression of angiotensin-converting enzyme-2 (ACE 2; receptors for coronavirus) in males than females, and sex-based immunological differences driven by the X chromosome and gender behavior (lifestyle), such as higher levels of smoking and drinking among men. In addition, the differences in mortality between men and women have been attributed to health-seeking behavior, where findings from the United States prior to the COVID-19 outbreak have indicated that women seek health care more actively than men [21]. Findings from Spain have also indicated that females had more responsible attitudes and preventive measure behaviors (such as frequent handwashing, mask wearing and obedience regarding stay-at-home orders) than men [22].

Experience from previous outbreaks has shown the necessity of integrating a gender analysis into the efforts of preparedness and response to ensure the improved effectiveness of health interventions and promotion of gender and health equity goals. The aim of this study was to compare morbidity and mortality during two years of the COVID-19 pandemic in Israel in female and male patients with COVID-19, as well as to assess length of stay, time of health-seeking behavior after positive diagnosis, and vaccination differences. To the authors’ knowledge, this is the first study that assesses the phenomena in the Israeli COVID-19 context, and which aims to integrate the above assessments to paint a more complete COVID-19 gender analysis.

2. Materials and Methods

2.1. Data Sources

A retrospective-archive study was conducted in Israel from 1 March 2020 to 1 March 2022 (two consecutive years). Data were obtained from the open COVID-19 database of the Israeli Ministry of Health’s (MOH), (https://data.gov.il/dataset/COVID-19 (accessed on 15 March 2022)), which encompasses information on 1270 localities and is updated daily. The database contains the number of COVID-19 diagnostic tests performed daily, confirmed cases (i.e., those that tested positive by real-time quantitative reverse-transcriptase polymerase-chain-reaction (qRT-PCR) assay—a person who tested positive was confirmed to be infected with COVID-19 regardless of the presence of any clinical symptoms and reoccurrence cases were removed in the dataset), classification of hospitalized patients, deaths by age, gender groups and vaccination status (four doses). Vaccination was documented as the number of those vaccinated in the first dose (starting from 20 December 2020), the number of those vaccinated in the second dose (as of 1 October 2021), the number of those vaccinated in the third dose (as of 30 July 2021), and the number of those vaccinated in the fourth dose (as of 2 January 2022). Hospitalized COVID-19 patients were classified according to WHO classification (mild, moderate, and severe disease, the latter classifica-
tion including patients who were intubated and mechanically ventilated). Classification of hospitalized patients was conducted according to the last status received that day (for example, if a hospitalized patient was admitted in a serious condition but, at the end of the day, his/her condition improved to moderate, the patient status was defined as moderate. The above variables were selected for assessment resulting from their completeness in the online database (as they were regularly updated by the Ministry of Health). Furthermore, the majority of these variables were the point of assessment in additional manuscripts on the subject.

2.2. Data Analysis

MOH data on confirmed COVID-19 cases, disease severity and deaths were analyzed by age and gender group. Status of hospitalized and severity status of COVID-19 (mildly ill, moderately ill, severely ill, critically ill and intubated patients, where patients were evaluated on the 11th day of each month) of the relevant month. The data from the Ministry of Health database became available on the 11 March 2020. Confirmed cases and deaths were calculated as a cumulative number for the relevant month. Rate of incidence cases in the population was the number of positive cases divided by the size of the relevant population group. The data were divided into five waves ((Wave 1—February–May 2020), (Wave 2—June–October 2020), (Wave 3—November 2020–March 2021), (Wave 4—April–October 2021), and (Wave 5—November 2021–March 2022)). A survival analysis was also performed for the patients who passed away (n = 10,145). The primary outcome variable was time to death, constructed as the time between date of being positive and death (failure), with censoring on 1 March 2022 for individuals who were alive by the end of the study period. We also included two secondary outcomes-time from being positive to hospital admission and in-hospital length of stay. The survival analysis included dichotomic values for gender and vaccination status (0 or 1—at least one dose). The Kaplan–Meier method was used to plot survival curves. These graphs served to test the proportional hazard assumption. We also conducted t-test analysis (for independent variables) to compare mean values. In addition, we conducted normality tests using the Kolmogorov-Smirnoff test. The data were analyzed using the statistical package software SPSS version 28 IBM SPSS 28.0 Statistics (IBM Corp. Released 2021. IBM SPSS Statistics for Windows, Version 28.0. IBM Corp., Armonk, NY, USA). The sample size calculation was calculated according to the guidelines of retrospective studies provided by Sackett, Haynes and Tugwell (1995) suggesting a need for 10 cases per variable [23].

3. Results

During the two years of the pandemic, 3,605,400 people were infected with the COVID-19 virus. Although the proportion of females (49.9%) and males (50.1%) is very similar in Israel, female infections are 1.12 times higher than males (n = 1,908,442 vs. n = 1,696,958), across almost all age groups, with the exception of the youngest (0–19) age groups. Despite this, less severe of illness and lower mortality were observed among women as compared to men, in all age groups; see Table 1.

In addition to the higher rate of confirmed cases among women, vaccination uptake was higher among women as compared to men for all doses. The relative risk (male/female) for the first, second, third and the fourth dose were: 0.967, 0.963, 0.958 and 0.936, respectively; see Table 2.
Table 1. Descriptive statistics of COVID-19 cases from 1 March 20 until 1 March 22, (n = 3,605,400).

| Age Group | Gender | Num. of Tests | Num. of Confirmed Cases | % of Confirmed Cases among Individuals Tested | Num. of Hospitalized | % of Hospitalized among Those Confirmed Cases | Num. of Deceased Cases | % of Deceased Cases among Those Confirmed Cases | Num. of Intubated Cases | % of Intubated Cases among Those Confirmed Cases | Num. of Severe and Critically Ill | % of Severe and Critically Ill among Those Confirmed Cases |
|-----------|--------|---------------|--------------------------|-----------------------------------------------|----------------------|-----------------------------------------------|------------------------|------------------------------------------------|------------------------|--------------------------------------------------|-----------------------------|--------------------------------------------------|
| 0–9       | Male   | 3,604,318     | 396,475                  | 11                                             | 2771                 | 0.699                                         | 7                      | 0.002                                          | 28                     | 0.007                                           | 100                         | 0.025                                           |
| 0–9       | Female | 3,614,679     | 303,633                  | 8.4                                            | 2254                 | 0.742                                         | 4                      | 0.001                                          | 13                     | 0.004                                           | 63                          | 0.021                                           |
| 10–19     | Male   | 3,612,414     | 400,978                  | 11.1                                           | 965                  | 0.241                                         | 7                      | 0.002                                          | 23                     | 0.006                                           | 70                          | 0.017                                           |
| 10–19     | Female | 3,592,314     | 366,416                  | 10.2                                           | 1090                 | 0.297                                         | 7                      | 0.002                                          | 20                     | 0.005                                           | 62                          | 0.017                                           |
| 20–29     | Male   | 3,607,403     | 223,659                  | 6.2                                            | 1524                 | 0.681                                         | 24                     | 0.011                                          | 49                     | 0.022                                           | 207                         | 0.093                                           |
| 20–29     | Female | 3,584,826     | 308,295                  | 8.6                                            | 4861                 | 1.577                                         | 21                     | 0.007                                          | 54                     | 0.018                                           | 247                         | 0.080                                           |
| 30–39     | Male   | 3,585,475     | 211,543                  | 5.9                                            | 2163                 | 1.022                                         | 50                     | 0.024                                          | 94                     | 0.044                                           | 568                         | 0.269                                           |
| 30–39     | Female | 3,614,929     | 303,654                  | 8.4                                            | 4937                 | 1.626                                         | 35                     | 0.012                                          | 92                     | 0.030                                           | 546                         | 0.180                                           |
| 40–49     | Male   | 3,632,673     | 188,899                  | 5.2                                            | 3469                 | 1.836                                         | 115                    | 0.061                                          | 241                    | 0.128                                           | 1308                        | 0.692                                           |
| 40–49     | Female | 3,617,795     | 264,099                  | 7.3                                            | 3444                 | 1.304                                         | 74                     | 0.028                                          | 138                    | 0.052                                           | 896                         | 0.339                                           |
| 50–59     | Male   | 3,567,629     | 124,867                  | 3.5                                            | 4735                 | 3.792                                         | 366                    | 0.293                                          | 518                    | 0.415                                           | 2160                        | 1.730                                           |
| 50–59     | Female | 3,612,021     | 169,765                  | 4.7                                            | 3772                 | 2.222                                         | 191                    | 0.113                                          | 249                    | 0.147                                           | 1493                        | 0.879                                           |
| 60–69     | Male   | 3,653,652     | 84,034                   | 2.3                                            | 6319                 | 7.520                                         | 947                    | 1.127                                          | 885                    | 1.053                                           | 3139                        | 3.735                                           |
| 60–69     | Female | 3,576,867     | 107,306                  | 3                                              | 4646                 | 4.330                                         | 524                    | 0.488                                          | 467                    | 0.435                                           | 2119                        | 1.975                                           |
| 70–79     | Male   | 3,735,333     | 44,824                   | 1.2                                            | 6714                 | 14.979                                        | 1550                   | 3.458                                          | 993                    | 2.215                                           | 3603                        | 8.038                                           |
| 70–79     | Female | 3,512,667     | 52,690                   | 1.5                                            | 5483                 | 10.406                                        | 975                    | 1.850                                          | 560                    | 1.063                                           | 2626                        | 4.984                                           |
| 80–89     | Male   | 3,516,000     | 17,580                   | 0.5                                            | 5439                 | 30.939                                        | 1795                   | 10.210                                         | 613                    | 3.487                                           | 2943                        | 16.741                                          |
| 80–89     | Female | 3,518,286     | 24,628                   | 0.7                                            | 5949                 | 24.155                                        | 1647                   | 6.688                                          | 464                    | 1.884                                           | 3006                        | 12.206                                          |
| 90+       | Male   | 4,099,000     | 4099                     | 0.1                                            | 1796                 | 43.816                                        | 803                    | 19.590                                         | 130                    | 3.172                                           | 990                         | 24.152                                          |
| 90+       | Female | 3,978,000     | 7956                     | 0.2                                            | 2700                 | 33.937                                        | 1070                   | 13.449                                         | 130                    | 1.634                                           | 1479                        | 18.590                                          |
Table 2. Differences in vaccination uptake between males and females.

| Gender       | First Dose | Second Dose | Third Dose | Fourth Dose |
|--------------|------------|-------------|------------|-------------|
| Male         | 3,273,901  | 2,881,961   | 2,166,722  | 351,205     |
| Female       | 3,372,618  | 2,979,819   | 2,252,895  | 373,638     |

Vaccinated per total male population

- Male: 0.68198
- Female: 0.704551

Vaccinated per total female population

- Male: 0.599647
- Female: 0.622494

Relative risk (Fraction of vaccinated males/Fraction of vaccinated females)

- Male: 0.967
- Female: 0.963

Corresponding to the above findings, a lower relative risk of diagnosis with COVID-19 was observed among men when compared to women (apart from the youngest (0–19) age groups); however, the relative risk of severe illness, intubation and mortality is higher among men. Furthermore, the relative risk between males and females in the youngest group (0–9) is observed to be larger, for example, in intubation, the relative risk is equal to 2.5; see Figure 1.

Figure 1. Relative risk between males and females (male/female), by age.

Figure 2 depicts changes over time in morbidity through five parameters, including hospitalization, mild, moderate and severe illness, and intubation for the five waves of the pandemic.

The hospitalization rate was higher among men compared to women for the entire pandemic period. These differences were higher in the beginning of pandemic (2020), but later become narrower, in 2021.

The differences in mild and moderate disease among men and women were interchanging and irregular. These findings were different in the case of severe and intubated cases. In the beginning of the pandemic, the observed gender gaps in the percentage of severe and intubated were wider between men and women. Between the end of the third wave and start of the fourth wave, the gap was attenuated wherever an alteration between gender groups (%) is observed; see Figure 2.
The differences in mild and moderate disease among men and women were interchanging and irregular. These findings were different in the case of severe and intubated cases. In the beginning of the pandemic, the observed gender gaps in the percentage of severe and intubated were wider between men and women. Between the end of the third wave and start of the fourth wave, the gap was attenuated wherever an alteration between gender groups (%) is observed; see Figure 2.

**Figure 2.** Gender trends in morbidity through five parameters including (**A**) hospitalization (out of all hospitalized), (**B**) mild, (**C**) moderate and (**D**) severe illness (among each respective population), and (**E**) intubation (among all intubated) throughout two years of the pandemic. The % males of each variable are the mirror reflection to the above data. Notes: The differences in all five trends are statistically significant according to the independent t-test. Statistical significance was defined as \( x < 0.05 \).

Figures 3–5 present survival analysis for deceased patients (\( n = 10,145 \)) where three parameters are examined, including time from positive diagnosis to death, in-hospital length of stay among deceased patients and time from positive diagnosis to hospital admission.
statistically significant according to the independent t-test. Statistical significance was defined as $p < 0.05$.

Figure 3 presents survival analysis for deceased patients ($n = 10,145$) where three parameters are examined, including time from positive diagnosis to death, in-hospital length of stay among deceased patients, and time from positive diagnosis to hospital admission. These parameters are presented according to vaccination status (0 or vaccinated with one dose) as well as by gender.

From the data, time from positive diagnosis to death and in-hospital length of stay are insignificant, whereas time from positive diagnosis to hospital admission is significant ($\text{Log rank} = 9.722; p = 0.002$) among the non-vaccinated population.

Among the deceased, 55.5% were men ($n = 5627$) and 44.5% were women ($n = 4518$). The mean number of days taken by unvaccinated men from positive diagnosis to hospital admission was greater ($\text{Mean} = 2.83, \text{SE} 23.2$) than that among unvaccinated women ($\text{Mean} = 1.69, \text{SE} 29.4$) ($t = -1.830, p = 0.034$).

Figure 3. Time from positive diagnosis to death (days) ($\text{Is_vaccinated 1} = \text{vaccinated with at least one dose}$).

| Vaccination status | gender | N  | Mean  | Std. Deviation | Std. Error Mean | $p$ value |
|--------------------|--------|----|-------|----------------|----------------|-----------|
| 0.00 Time from positive to death | Male | 3935 | 18.9144 | 27.94992 | 0.44556 | 0.284 |
|                   | Female| 3258 | 18.1304 | 34.05427 | 0.59662 |          |
| 1.00 Time from positive to death | Male | 1692 | 18.3174 | 44.78087 | 1.08866 | 0.317 |
|                   | Female| 1260 | 20.1929 | 54.06888 | 1.52322 |          |

Figure 4. Length of stay (LOS) ($\text{Is_vaccinated 1} = \text{vaccinated with at least one dose}$).

| Vaccination status | gender | N  | Mean  | Std. Deviation | Std. Error Mean | $p$ value |
|--------------------|--------|----|-------|----------------|----------------|-----------|
| 0.00 Length of stay | Male | 3935 | 15.4562 | 20.79011 | 0.33142 | 0.516 |
|                   | Female| 3258 | 15.0064 | 34.70963 | 0.60810 |          |
| 1.00 Length of stay | Male | 1692 | 13.6206 | 32.96313 | 0.80136 | 0.433 |
|                   | Female| 1260 | 14.8476 | 47.71286 | 1.34416 |          |

Figure 4. Length of stay (LOS) ($\text{Is_vaccinated 1} = \text{vaccinated with at least one dose}$).
Figure 5. Time from positive diagnosis to hospital admittance (Is vaccinated 1 = vaccinated with at least one dose).

These parameters are presented according to vaccination status (0 or vaccinated with one dose) as well as by gender. From the data, time from positive diagnosis to death and in hospital length of stay are insignificant, whereas time from positive diagnosis to hospital admission is significant ($Lon \text{rank} = 9.722; p = 0.002$) among the non-vaccinated population.

Among the deceased, 55.5% were men ($n = 5627$) and 44.5% were women ($n = 4518$). The mean number of days taken by unvaccinated men from positive diagnosis to hospital admission was greater (mean = 2.83, SE 23.2) than that among unvaccinated women (mean = 1.69, SE 29.4) ($t = -1.830, p = 0.034$).

4. Discussion

Pandemics and recessions have the potential to exacerbate health inequalities [24]. For the response to disease outbreaks such as COVID-19 to be effective and not reproduce or perpetuate gender and health inequities, it is important that gender relations that influence differential vulnerability to infection, exposure to pathogens, and treatment received, must be considered, and addressed. The findings of this study in Israel indicate that women have a higher risk of infection but are less severely ill. These findings are in line with much of the previous conclusions in the literature, that more severe illness is observed in men [7–11,25]; however, in contrast to previous data, we found women to have a higher incidence of viral infections [26], where Krause et al. (2020) found that women have a higher viral infection incidence.

To explain the above gender gaps in the context of COVID-19 morbidity and mortality in Israel, several additional findings from the current study may partially explain the above phenomenon. As shown, the higher vaccination rates in women may play a protective role against the higher severity of adverse outcomes observed in men [27]. Interestingly, in contrast to our findings, a meta-analysis indicated that a majority (58%) of papers reported men as having higher intentions to get vaccinated against COVID-19 as compared to women [28]. Even findings from Israel from the beginning of the vaccination rollout campaign indicated that women were more hesitant to be vaccinated [10].
Moreover, a noteworthy component is that, despite the higher vaccination rates among women, we observe a higher incidence of infection. This may be explained by exposure risk, where women face a higher exposure to disease. For example, in terms of occupational exposure, women make up a large percentage of healthcare workers globally and may play a role as the healthcare sector faces a higher risk through interaction with patients and interaction with other healthcare workers [29].

Additionally, it has been documented that women are more likely to have the role of primary caregivers and be involved frontline interactions with communities for essential demands [30,31]. These social commitments may be the partial exposure source for a higher risk of contagion among women as compared to males.

In addition to these elements, our findings indicate that time from positive diagnosis to hospital admission is higher among unvaccinated men than women among those who passed away, indicating that differences in health-seeking behavior may also explain the differences in mortality, where the active seeking of care by men only occurs when the condition reaches a grave stage. Overall, the findings point to the fact that males may downplay the disease, and report for testing less in the case of slight illness, resulting in a worse aggregated picture (where more severe cases are observed among the population, while lighter ones go unidentified). The literature also has probed additional explanations for the unequal distribution of disease severity and mortality between genders, including a multifactorial phenomenon involving lifestyle differences, differences in prevalence of underlying conditions (e.g., heart disease and diabetes), a stronger immune system among women, etc. [13,32].

The above findings regarding influential factors on health-seeking behavior (hospital admission time) and vaccination differences may be indicative of a general higher risk perception among women, resulting in a higher likelihood of practicing preventive behaviors and avoidance of risk behaviors, as previously presented in findings from Spain [22,33].

Our findings indicate that health trends cannot necessarily be generalized to all countries and are very much dynamic and contingent on socio-geographical context. In addition, it is necessary to consider the specific characteristics of the disease and the various risk factors and their interaction with one another when defining an individual’s vulnerability to the impacts of COVID-19. Targeted approaches, which take into consideration sex and gender and the intersecting factors, are necessary to engage in the fight against COVID-19 to ensure the most effective and equitable pandemic response. Examples of such targeted responses, include tailored risk communication campaigns and health communication strategies which take into consideration the sex and gender component and better reflect the vulnerability of the population groups. Furthermore, further studies are needed to decipher the role of genetic, biological cultural, psychological, and environmental components that may play an important role in the varied vulnerability of the population groups.

5. Limitations of This Study

Several limitations of this study must be considered. The current study is based on the Open Database of the Israeli Ministry of Health, which contains aggregated data regarding vaccination and confirmation rate. In the absence of individual-level data, analyses and conclusions are purely ecological for theses variables. Despite vaccination of large proportions of the population, new variants continue, challenging the healthcare system, and contributing to a fifth and potential future waves. The findings of this study may reduce the ability to forecast the gender attributes of the “upcoming” waves.

The analysis included repeated COVID-19 tests since some people do multiple tests before being labeled “confirmed”. Indeed, it might lead to an underestimation of the true rate of confirmed tests. However, since the national method of data collection and reporting has been stable throughout the months of the pandemic, and since, at the time of the study, COVID testing was free of charge for the entire Israeli population, we believe that this should not create a bias. Furthermore, once an individual is labeled as positive, the positive reoccurrence cases have been removed in the MOH COVID-19 database. In addition, we
do not have access to data regarding hospitalization characteristics for deceased patients (e.g., complications, intubation days, ECMO use and other cardiovascular support).

6. Conclusions

This study offers an important longitudinal dataset of two years to explore how sex may have played a factor in variations in COVID-19 transmission, illness, and death in Israel. The findings of this study indicate that female infections, across almost all age groups, are 1.12 times more likely (apart from the youngest (0–19) age groups). Despite this, the relative risk of severe illness, intubation and mortality is higher among men throughout the two years of the pandemic. In addition, our findings indicate that the mean number of days taken by unvaccinated men from positive diagnosis to hospital admission was greater than among unvaccinated women among the deceased population, potentially indicating that differences in health-seeking behavior may also contribute to differences in mortality in this context. Going forward, the results of this study indicate that targeted approaches, which take into consideration sex and gender and the intersecting factors, are necessary to engage in the fight against COVID-19 to ensure the most effective and equitable pandemic response. Furthermore, additional studies are needed in the future to elucidate the role of genetic, biological, cultural, psychological, and environmental components that may play an important role in varied vulnerability of differing population groups. A better understanding of the assorted factors are necessary to enhance the strategies that are utilized to promote preventive behavior, alongside adapting treatment protocols and therapies to respond to the differences in disease course.

Author Contributions: Conceptualization, A.K. and M.S.; methodology, M.S.; validation, A.K. and M.S.; formal analysis, M.S.; investigation, A.K.; data curation, A.K. and M.S.; writing—original draft preparation, A.K.; writing—review and editing, M.S. and S.B.S.; supervision, M.S. and S.B.S.; project administration, A.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical approval was not required since all data used in this study were obtained from the publicly available open COVID database website, https://datadashboard.health.gov.il/COVID-19/general (accessed on 15 March 2022). No individual data were included in the study.

Informed Consent Statement: Patient consent was waived due to no individual data being used in this study.

Data Availability Statement: Links to publicly archived dataset: https://datadashboard.health.gov.il/COVID-19/general (accessed on 15 March 2022).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. Available online: https://coronavirus.jhu.edu/map.html (accessed on 17 April 2020).
2. Vom Steeg, L.G.; Klein, S.L. SeXX Matters in Infectious Disease Pathogenesis. PLoS Pathog. 2016, 12, e1005374. [CrossRef] [PubMed]
3. Ursin, R.L.; Klein, S.L. Sex Differences in Respiratory Viral Pathogenesis and Treatments. Annu. Rev. Virol. 2021, 8, 393–414. [CrossRef] [PubMed]
4. Ingersoll, M.A. Sex differences shape the response to infectious diseases. PLoS Pathog. 2017, 13, e1006688. [CrossRef] [PubMed]
5. Alghamdi, I.; Hussain, I.; Alghamdi, M.; Almalki, S.; Alghamdi, M.; Elsheemy, M. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int. J. Gen. Med. 2014, 7, 417–423. [CrossRef]
6. Karlberg, J.; Chong, D.S.Y.; Lai, W.Y.Y. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory Syndrome than Women Do? Am. J. Epidemiol. 2004, 159, 229–231. [CrossRef] [PubMed]
7. Jin, J.M.; Bai, P.; He, W.; Wu, F.; Liu, X.F.; Han, D.M.; Liu, S.; Yang, J.K. Gender Differences in Patients with COVID-19: Focus on Severity and Mortality. Front. Public Health 2020, 8, 152. [CrossRef]
8. Klein, S.L.; Dhakal, S.; Ursin, R.L.; Deshpande, S.; Sandberg, K.; Mauvais-Jarvis, F. Biological sex impacts COVID-19 outcomes. *PLoS Pathog.* 2020, 16, e1008570. [CrossRef] [PubMed]

9. Márquez, E.J.; Trowbridge, J.; Kuchel, G.A.; Bachereau, J.; Ucar, D. The lethal sex gap: COVID-19. *Immun. Ageing* 2020, 17, 13. [CrossRef]

10. Green, M.S.; Nitzan, D.; Schwartz, N.; Niv, Y.; Peer, V. Sex differences in the case-fatality rates for COVID-19—A comparison of the age-related differences and consistency over seven countries. *PLoS ONE* 2021, 16, e0250523. [CrossRef]

11. Sieber, P.; Flury, D.; Güsewell, S.; Albrich, W.C.; Boggian, K.; Gardiol, C.; Schlegel, M.; Sieber, R.; Vernazza, P.; Kohler, P. Characteristics of patients with Coronavirus Disease 2019 (COVID-19) and seasonal influenza at time of hospital admission: A single center comparative study. *BMC Infect. Dis.* 2021, 21, 27. [CrossRef]

12. Gadi, N.; Wu, S.C.; Spilman, A.P.; Moulton, V.R. What’s Sex Got to Do with COVID-19? Gender-Based Differences in the Host Immune Response to Coronavirus. *Front. Immunol.* 2020, 11, 2147. [CrossRef] [PubMed]

13. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Qu, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. Clinical Characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 2020, 382, 1708–1720. [CrossRef] [PubMed]

14. Zhao, S.; Cao, P.; Chong, M.K.; Gao, D.; Lou, Y.; Ran, J.; Wang, K.; Wang, W.; Yang, L.; He, D.; et al. The time-varying serial interval of the coronavirus disease (COVID-19) and its gender-specific difference: A data-driven analysis using public surveillance data in Hong Kong and Shenzhen, China from January 10 to February 15, 2020. *Infect. Control Hosp. Epidemiol.* 2020, 10, 1–8.

15. Mo, P.; Xing, Y.; Xiao, Y.U.; Deng, L.; Zhao, Q.; Wang, H.; Xiong, Y.; Cheng, Z.; Gao, S.; Liang, K.; et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. *Clin. Infect. Dis.* 2021, 73, e4208–e4213. [CrossRef] [PubMed]

16. Acheampong, D.O.; Barffour, I.K.; Boye, A.; Aninagyei, E.; Ocansey, S.; Morna, M.T. Male predisposition to severe COVID-19: Review of evidence and potential therapeutic prospects. *Biomed. Pharmacother.* 2020, 131, 110748. [CrossRef]

17. Kocher, K.; Delot-Vilain, A.; Spencer, D.; LoTempio, J.; Delot, E.C. Paucity and Disparity of Publicly Available Sex-Disaggregated Data for the COVID-19 Epidemic Hamper Evidence-Based Decision-Making. *Arch. Sex. Behav.* 2021, 50, 407–426. [CrossRef]

18. de Souza, A.P.G.; Mota, C.M.D.M.; Rosa, A.G.F.; de Figueiredo, C.J.J.; Candeias, A.L.B. A spatial-temporal analysis at the early stages of the COVID-19 pandemic and its determinants: The case of Recife neighborhoods, Brazil. *PLoS ONE* 2022, 17, e0268538. [CrossRef]

19. Danielsen, A.C.; Boullicault, M.; Gompers, A.; Rushovich, T.; Lee, K.M.N.; Richardson, S.S. How Cumulative Statistics Can Mislead: The Temporal Dynamism of Sex Disparities in COVID-19 Mortality in New York State. *Int. J. Environ. Res. Public Health* 2022, 19, 14066. [CrossRef]

20. Bwire, G.M. Coronavirus: Why Men are More Vulnerable to Covid-19 Than Women? *SN Compr. Clin. Med.* 2020, 2, 874–876. [CrossRef]

21. Thompson, A.E.; Anisimowicz, Y.; Miedema, B.; Hogg, W.; Wodchis, W.P.; Aubrey-Bassler, K. The influence of gender and other patient characteristics on health care-seeking behaviour: A QUALICOPC study. *BMC Fam. Pract.* 2016, 17, 38. [CrossRef]

22. De La Vega, R.; Ruiz-Barquin, R.; Boros, S.; Szabo, A. Could attitudes toward COVID-19 in Spain render men more vulnerable than women? *Glob. Public Health* 2020, 15, 1278–1291. [CrossRef]

23. Sackett, D.L.; Haynes, R.B.; Tugwell, P. *Clinical Epidemiology: A Basic Science for Clinical Medicine*; Little, Brown and Company: Boston, MA, USA, 1985.

24. Aleksanyan, Y.; Weinman, J.P. Women, men and COVID-19. *Soc. Sci. Med.* 2022, 294, 114698. [CrossRef] [PubMed]

25. Tabata, S.; Imai, K.; Kawano, S.; Ikeda, M.; Kodama, T.; Miyoshi, K.; Obinata, H.; Mimura, S.; Kodera, T.; Kitagaki, M.; et al. Clinical characteristics of coronavirus disease 2019 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: A retrospective analysis. *Lancet Infect. Dis.* 2020, 20, 1043–1050. [CrossRef] [PubMed]

26. Krause, P.R.; Fleming, T.R.; Peto, R.; Longini, I.M.; Figueroa, J.P.; Sterne JA, C.; Cravioto, A.; Rees, H.; Higgins JP, T.; Boutron, I.; et al. Considerations in boosting COVID-19 vaccine immune responses. *Lancet* 2021, 398, 1377–1380. [CrossRef] [PubMed]

27. Capuano, A.; Rossi, F.; Paolillo, G. Covid-19 Kills More Men Than Women: An Overview of Possible Reasons. *Front. Cardiovasc. Med.* 2020, 7, 131. [CrossRef] [PubMed]

28. Zintel, S.; Flock, C.; Arbogast, A.L.; Forster, A.; von Wagner, C.; Sieverding, M. Gender differences in the intention to get vaccinated against COVID-19: A systematic review and meta-analysis. *J. Public Health 2022*, 17, 1–25. [CrossRef]

29. Purkayastha, D.; Vanroelen, C.; Bircan, T.; Vantyghem, M.A.; Gantelet Adsera, C. Work, Health and COVID-19: A Literature Review. *SSRN Electron. J.* 2021, 5, 634–653. [CrossRef]

30. Mantovani, A.; Dalbeni, A.; Beatrice, G. Coronavirus disease 2019 (COVID-19): We don’t leave women alone. *Int. J. Public Health* 2020, 65, 235–236. [CrossRef]

31. Wenham, C.; Smith, J.; Morgan, R. Gender and COVID-19 Working Group. COVID-19: The gendered impacts of the outbreak. *Lancet* 2020, 395, 846–848. [CrossRef]

32. Forsblom, E.; Sälen, S.; Kortela, E.; Ahava, M.; Kreivi, H.-R.; Holmberg, V.; Järvinen, A.; Hästbacka, J.; Kivivuori, S.-M.; Meretoja, A. Male predominance in disease severity and mortality in a low Covid-19 epidemic and low case-fatality area—A population-based registry study. *Infect. Dis.* 2021, 53, 789–799. [CrossRef]

33. Gerhold, L. COVID-19: Risk Perception and Coping Strategies. *PsyArXiv* 2020, 1–11. [CrossRef]